Characteristics of hepatitis C virus among intravenous drug users in Iceland

American Journal of Epidemiology

Volumn 143, Issue 6, 1996, Pages 631-636

  Löve, Arthur ^a   Sigurdsson, Jon R ^a,b   Stanzeit, Barbara ^a   Briem, Haraldur ^a   Rikardsdottir, Hugrun ^a   Widell, Anders ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LUND UNIVERSITY   (Sweden)

Author keywords

genotype; hepatitis C viruses; intravenous; sex factors; substance abuse; viremia

Indexed keywords

LIVER ENZYME; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; ICELAND; IMMUNOBLOTTING; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VIREMIA; VIRUS STRAIN;

EID: 0029932394     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008793     Document Type: Article

References (29)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-8.
3. Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 1974;2:241-6.
4. Feinstone SM, Kapikian AZ. Purcell RH, et al. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70.
5. Knodell RG, Conrad ME, Ishak KG. Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis: role of gamma-globulin prophylaxis in its prevention. Gastroenterology 1977;72:902-9.
6. Berman M, Alter HJ. Ishak KG, et al. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med 1979;91:1-6.
7. Realdi G, Alberti A, Rugge M, et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982;23:270-5.
8. Esteban JI, Esteban R. Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-7.
9. Love A, Stanzeit B. Hepatitis C virus infection in Iceland: a recently introduced blood-borne disease. Epidemiol Infect 1994;113:529-36.
10. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
11. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
12. Chan SW, McOmish F, Holmes EC, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992;73:1131-41.
13. Widell A, Shev S, Månson S, et al. Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemioloaical applications. J Med Virol 1994;44:272-9.
14. Widell A, Månsson AS, Sundström G, et al. Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays. J Med Virol 1991;35:253-8.
15. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;362:156-9.
16. Dean AG, Dean JA, Burton AH, et al. Epi Info, version 5: a word processing, database, and statistics program for epidemiology on microcomputers. Atlanta, GA: Centers for Disease Control, 1990.
17. Wang Y, Okamoto H, Tsuda F, et al. Prevalence, genotypes, and an isolate (HC-C2) of hepatitis C virus in Chinese patients with liver disease. J Med Virol 1993;40:254-60.
18. Cha TA, Beall E, Irvine B, et al. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci USA 1992;89:7144-8.
19. Hansson BG, Moestrup T, Widell A, et al. Infection with delta agent in Sweden: introduction of a new hepatitis agent. J Infect Dis 1982;146:472-8.
20. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994;8:223-31.
21. Vlahov D. HIV seroconversion studies among intravenous drug users. (Editorial). AIDS 1994;8:263-5.
22. Robert-Guroff M, Weiss SH, Giron JA, et al. Prevalence of antibodies to HTLV-1. -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255:3133-7.
23. Baxter DN, Moran A. Acute hepatitis B infection in Stockport during 1984 and 1985. Community Med 1988;10:298-305.
24. Christenson B. Epidemiology of hepatitis B in Sweden. J Infect 1987;15:269-77.
25. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-8.
26. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-44.
27. Löve A, Smáradóttir A, Thorsteinsson SB, et al. Hepatitis C virus genotypes among blood donors and their recipients in Iceland determined by the polymerase chain reaction (PCR). Vox Sang 1995;69:18-22.
28. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccination protocol recommendations. Am J Med 1989;87(suppl 3A): 36S-40S.
29. Tilzey AJ, Palmer SJ, Barrow S, et ai. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992;304:1272-6.